2886 results about "Threonine" patented technology

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

An amino acid such as threonine, homoserine, isoleucine, lysine, valine and tryptophan is produced using a bacterium belonging to the genus Escherichia which has been constructed from sucorse non-assimilative strain belonging to the genus Escherichia and which harbors sucrose non-PTS (phosphoenol pyruvate-dependent sucrose-6-phosphotransferase system) genes and has an ability to produce the amino acid.

This invention relates to a method for prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and / or inhibition of the signal transduction pathway.

A bacterial strain of Escherichia coli is described which produces L-threonine, and is obtained by a process comprising transduction by bacteriophage P1 which bears a transposon which inactivates threonine dehydrogenase activity, and isolation of a transductant lacking threonine dehydrogenase activity.

The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.

Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2—R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl groupR2 is H or a substituentR3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic groupn is an integer from 0 to 1Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine / threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

The present invention relates to a method for treating cancer using p38 / JTV-1 and a method for screening pharmaceutical composition for treating cancer. More particularly, this invention relates to the method for treating cancer, which comprises administering the effective amount of p38 / JTV-1 protein or a nucleic acid encoding for said protein to the patient and the method for screening a pharmaceutical composition for treating cancer characterized by selecting a substance having an effect on the increase of the activity of the p38 / JTV-1 protein and the intracellular level thereof.The method according to the invention can be effectively used to treat cancer through the mechanism of suppressing the proliferation of cancer cells by binding to FBP (FUSE-binding protein) and thereby promoting the ubiquitination of FBP to downregulate c-myc gene, which is a proto-oncogene, and the mechanism of promoting the apoptosis of cells by binding to PDK-1 (phosphoinositide-dependent protein) and thereby inhibiting the phosphorylation of AKT (serine / threonine kinase). Also, p38 / JTV-1 can be used as a target for screening of new anticancer agents, by virtue of such regulation mechanisms of p38 / JTV-1.

L-Methionine is produced by culturing a microorganism which is deficient in repressor of L-methionine biosynthesis system and / or enhanced intracellular homoserine transsuccinylase activity is cultured in a medium so that L-methionine should be produced and accumulated in the medium, and collecting the L-methionine from the medium. The microorganism preferably further exhibits reduced intracellular S-adenosylmethionine synthetase activity, L-threonine auxotrophy, enhanced intracellular cystathionine γ-synthase activity and enhanced intracellular aspartokinase-homoserine dehydrogenase II activity. The present invention enables breeding of L-methionine-producing bacteria, and L-methionine production by fermentation.

Transgenic plants containing free amino acids, particularly at least one amino acid selected from among glutamic acid, asparagine, aspartic acid, serine, threonine, alanine and histidine accumulated in a large amount, in edible parts thereof, and a method of producing them are provided. In this method, glutamate dehydrogenase (GDH) gene is introduced into a plant together with a regulator sequence suitable for over expressing the sequence encoding GDH gene in plant cells.

The invention belongs to the field of feeds, and particularly relates to a six percent-premix for lactating sows and a wheat-type daily ration prepared from the six percent-premix. The premix comprises multivitamins, composite trace elements, DL-methionine, lysine, threonine, L-arginine, valine, composite electrolyte, compound enzyme, 5000 IU of phytase, functional additives, feed attractants, calcium hydrogen phosphate, stone powder, salt, choline, antioxidants and defatted rice bran. On the whole, the daily ration for the lactating sows is capable of protecting the development of mammary glands of the sows, ensuring plentiful milk with high quality in the lactation period of the sows and increasing the survival rate of suckling piglets, and enables the piglets to have higher weaning weight.

Polymerase chain reaction primers and methods directed to detecting the EGFR mutant C→T at the position corresponding to base 2369 of EGFR cDNA. The invention provides a PCR primer that hybridizes under suitable PCR conditions to a polynucleotide sequence 5′ in each respective strand to a mutation of an EGFR gene that encodes a substitution of threonine by methionine at position 790 of the EGFR polypeptide. The invention also provides a PCR primer hybridizes to a sequence that includes a mutant T at the position corresponding to base 2369 of EGFR cDNA but not to a second EGFR polynucleotide containing a wild type C. The invention provides several methods and kits for detecting a mutant epidermal growth factor receptor (EGFR) gene in a sample comprising probing the sample with a means for selectively detecting a nucleotide sequence comprising a mutant T at the position corresponding to base 2369 of EGFR cDNA, and identifying that the base at said position is T. These methods and kits are also useful to predict resistance to the therapeutic effects of gefitinib or erlotinib in a subject suffering from or suspected of having a cancer.

The present invention is directed in part towards methods of modulating the function of serine / threonine protein kinases with azabenzimidazole-based compounds. The methods incorporate cells that express a serine / threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine / threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to azabenzimidazole compounds and pharmaceutical compositions comprising these compounds.

A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning. Preferably, the composition of bio-active compounds includes a combination of 4-hydroxyisoleucine with at least one amino acid selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate and tyrosine. In one presently preferred embodiment of the present invention, the combination is derived, isolated, and / or extracted from fenugreek seeds. Methods for using a novel composition of bio-active compounds from fenugreek seed for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning are also disclosed, wherein methods comprise the steps of: (1) providing an effective amount of a composition of bio-active compounds derived, isolated, and / or extracted from fenugreek seeds; and (2) administering the composition to a human or animal.

The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

The invention discloses a corn type mixed feed for a weaned pig and a preparation method thereof. The mixed feed comprises the following raw materials: dried corn, puffed corn, soybean meal, puffed soybean, a wheat germ cake, flour, fish meal, plasma protein powder, whey powder, soya-bean oil, stone flour, calcium hydrogen phosphate, salt, lysine 70%, methionine 99%, threonine 99%, choline chloride 60%, glucose, compound enzyme, a vitamin premix and a trace element premix. The preparation method comprises the following steps: crushing; mixing; and granulation. The invention has the following beneficial effects: nutritional requirements of the weaned pig are met; the mixed feed has good palatability and a high digestive rate and can reduce various discomforts caused by weaning stress, enhance the immunity of the weaned pig, improve food consumption and productivity of the weaned pig, promote rapid and healthy growth of the weaned pig and guarantee the survival rate of the weaned pig.

The invention provides compound feed for teaching piglets to eat foods other than breast milk, which is used for weaning piglets and teaching the piglets to eat foods other than breast milk, and comprises the following components in part by weight: 212.4 parts of corn starch, 154.0 parts of bulked corn, 100.0 parts of 46 percent of bulked bean pulp, 40 parts of fish meal, 100 parts of wheat flour, 5 parts of calcium powder, 21 parts of calcium hydrophosphate, 2 parts of table salt, 20 parts of soybean oil, 5 parts of lysine, 2 parts of threonine, 1.5 parts of choline chloride, 10 parts of premix, 0.2 part of complex enzyme, 0.3 part of pig Duowei, 0.2 part of sweetener, 0.3 part of flavouring agent, 3 parts of baking soda, 20 parts of cane sugar, 30 parts of glucose, 50 parts of egg powder, 70 parts of soy protein concentrate, 50 parts of fermented bean pulp, 6 parts of acidizer, 100 parts of whey powder, 0.5 part of mould removing agent, 0.3 part of antioxidant and 0.3 part of mildewpreventive. In the invention, the problems of incomplete immune functions, low disease resistance, inadequate digestive ferment, incomplete upper gastrointestinal development, low digestion and absorption ability, susceptibility to diarrhea and the like of piglets.

The present invention is a substantially purified sortase-transamidase enzyme from Gram-positive bacteria, such as Staphylococcus aureus. The enzyme having a molecular weight of about 23,539 or about 29,076 daltons and catalyzing a reaction that covalently cross-links the carboxyl terminus of a protein having a sorting signal to the peptidoglycan of a Gram-positive bacterium, the sorting signal having: (1) a motif of LPX3X4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X3 is any of the twenty naturally-occurring L-amino acids and X4 is selected from the group consisting of alanine, serine, and threonine, and wherein sorting occurs by cleavage between the fourth and fifth residues of the LPX3X4G motif. Variants of the enzyme, methods for cloning the gene encoding the enzyme and expressing the cloned gene, and methods of use of the enzyme, including for screening for antibiotics and for display of proteins or peptides on the surfaces of Gram-positive bacteria, are also disclosed.

The invention discloses a method for producing L-2-aminobutyric acid, and the method comprises the following step: catalyzing L-threonine utilized as a raw material through an enzyme catalysis system consisting of threonine deaminase, L-amino acid dehydrogenase and coenzyme regeneration systems, thus producing the L-2-aminobutyric acid. The method for producing theL-2-aminobutyric acid has the advantages that the raw material is low in price, the property is stable, and the production cost of the L-2-aminobutyric acid can be greatly lowered, the conversion rate and product concentricity are high, no influence caused by byproducts exists, and the method is suitable for industrialization application.

The invention relates to a pig feed, in particular to a nursery pig concentrated feed, comprising the following raw materials by weight proportion: 30-50 of sucking pig composite vitamin, 30-50 of low copper mineral element, 60-100 of peeled soybean meal, 100-180 of fermented soybean meal, 100-150 of extruded soybean, 110-180 of steam fish meal, 50-100 of dried porcine soluble, 60-120 of acid whey powder, 80-90 of glucose powder, 5-10 of glutamine, 80-100 of chyle fat powder, 40-49 of calcium carbonate, 12-14 of basic zinc chloride, 4-6 of salt, 55-60 of calcium biphosphate, 6-10 of sodium butyrate, 12-15 of lysine, 6-8 of threonine, 4-6 of TP-100 enzyme, 4-5 of cysteine, 5-7 of se-enriched yeast and 6-10 of copper chloride hydroxide. The nursery pig concentrated feed has the advantages of milk nutrition composition simulation, good palatability, high digestibility, large feed intake because the baby pigs like to eat and improvement of survival rate as well as immunity of the nursery pigs.

The invention belongs to the field of fermented waste liquid treatment in the biological fermentation industry and discloses a fertilizer prepared by utilizing threonine fermented wastes. The fertilizer is prepared by the following steps: (1) preparing threonine fermentation liquor; (2) filtering and discoloring; (3) separating crystals and a mother solution; (4) hydrolyzing mycoprotein; (5) preparing feed liquid A; and (6) preparing the fertilizer. According to the fertilizer, amino acid fermented wastes are effectively utilized, the production cost of the fertilizer is reduced, the wastes are changed into valuable materials, the fertilizer efficiency is lasting, and the fertilizer is superior to like products in the market.

The invention provides feed for improving growth performances of broiler chickens. The feed comprises a main feed ingredient, bone meal, rapeseed meal, monocalcium phosphate, vitamin E, vitamin K, pantothenic acid, lysine, methionine, threonine, sodium butanoate, enzyme additives, probiotics additives, microelement additives and Chinese medicinal herb additives. The feed can well solve the problem that the feed digestion capability of the broiler chickens is poor, effectively controls pathogenic microorganisms, promotes digestion and immunity of the broiler chickens in the growing process, improves growth performances of the broiler chickens, reduces morbidity and mortality of the broiler chickens and reduces medicine residue rate of antibiotics and chemical synthesis medicines in the broiler chickens.

The invention discloses a nonreactive health powdered suckling pig creep compound feed and a preparation method thereof, wherein the feed is prepared from the following materials: corn, broken rice, puffed corn starch, puffed soybean meal, dehulling soybean meal, fermented soybean meal, white fish meal, flour, plasma protein flour, whey powder, fruit sugar, glucose monohydrate, bean oil, calcium formate, calcium biphosphate, salt, enveloped slow release acidulant, choline chloride, suckling pig compound premix, zinc oxide, yeast cell wall polysaccharides, sodium glutamate, arazyme, lipidase, Clostridium butyricum, essential oils, L-lysine hydrochloride, DL methionine, L-threonine, tryptophan and phytase. Based on the physiological characteristics of suckling pig and by the combination of various materials, the feed is supplementary in nutrition and high in design of amino acid and daily ration of energy without adding antibiotics, and Clostridium butyricum and various essential oils are used for protecting the health; therefore, the feed intake of suckling pig can be increased, the weight growth rate is increased, the diarrhea rate after ablactation is reduced, the intestine health of suckling pig can be improved, the immunity is improved, and the survival rate of suckling pig is increased.

The invention includes a method for harvesting a polypeptide produced by a host cell, wherein the polypeptide has not undergone intracellular posttranslational modification, such as dehydration of a serine or a threonine, and / or thioether bridge formation. The invention also includes a method for producing thioether-containing peptides and dehydroalanine / dehydrobutyrine-containing.peptides, wherein thioether rings may be formed extracellularly.